Fibrogen Inc (KYNB) — 8-K Filings

8-K Filings (22)

• FibroGen, Inc. Files 8-K Report — Nov 6, 2025 Risk: medium
  On November 6, 2025, FibroGen, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details regarding th
• FibroGen Completes Asset Acquisition — Sep 5, 2025 Risk: medium
  FibroGen, Inc. announced the completion of its acquisition of assets on August 29, 2025. The company, incorporated in Delaware, filed its 8-K report on Septembe
• FibroGen, Inc. Files 8-K Reporting Other Events — Sep 2, 2025 Risk: low
  FibroGen, Inc. filed an 8-K on August 29, 2025, reporting other events and financial statements. The filing details the company's principal executive offices lo
• FibroGen Inc. Files 8-K Report — Aug 18, 2025 Risk: low
  On August 18, 2025, FibroGen, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific m
• FibroGen Enters Material Definitive Agreement — Aug 14, 2025 Risk: medium
  FibroGen, Inc. entered into a Material Definitive Agreement on August 12, 2025. The company, headquartered in San Francisco, CA, filed an 8-K report detailing t
• FibroGen Files 8-K: Material Agreement and Exhibits — Jul 14, 2025 Risk: medium
  On July 14, 2025, FibroGen, Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial statements and e
• FibroGen Terminates Material Definitive Agreement — Jun 13, 2025 Risk: medium
  FibroGen, Inc. announced on June 12, 2025, the termination of a material definitive agreement. The company, headquartered in San Francisco, California, filed th
• FibroGen Files 8-K on Security Holder Rights — Jun 12, 2025 Risk: medium
  FibroGen, Inc. filed an 8-K on June 12, 2025, reporting a material modification to the rights of security holders and amendments to its articles of incorporatio
• FibroGen Reports Material Agreement, Officer Changes — Jun 9, 2025 Risk: medium
  FibroGen, Inc. filed an 8-K on June 9, 2025, reporting several key events as of June 4, 2025. These include entering into a material definitive agreement, chang
• FibroGen Files 8-K: Bylaws Amended, Financials Filed — Apr 4, 2025 Risk: low
  FibroGen, Inc. filed an 8-K on April 4, 2025, reporting an amendment to its Articles of Incorporation or Bylaws and the filing of financial statements and exhib
• FibroGen Inc. Files 8-K — Mar 31, 2025 Risk: low
  FibroGen, Inc. filed an 8-K on March 31, 2025, reporting an event that occurred on March 28, 2025. The filing is categorized under Regulation FD Disclosure. No
• FibroGen Enters Material Definitive Agreement — Mar 28, 2025 Risk: medium
  On March 28, 2025, FibroGen, Inc. reported the entry into a material definitive agreement. The filing does not provide specific details about the agreement, suc
• FibroGen Files 8-K: Material Agreement & Exhibits — Feb 24, 2025 Risk: medium
  On February 24, 2025, FibroGen, Inc. filed an 8-K report indicating an entry into a material definitive agreement and the filing of financial statements and exh
• FibroGen Reports 8-K with Material Agreements & Officer Changes — Feb 20, 2025 Risk: medium
  FibroGen, Inc. filed an 8-K on February 20, 2025, reporting on a material definitive agreement, results of operations, director/officer changes, and regulatory
• FibroGen Announces Board and Executive Changes — Dec 16, 2024 Risk: medium
  On December 16, 2024, FibroGen, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the depart
• FibroGen Terminates Material Definitive Agreement — Oct 3, 2024 Risk: medium
  FibroGen, Inc. reported on September 27, 2024, the termination of a material definitive agreement. The filing does not specify the counterparty or the nature of
• FibroGen Inc. Faces Delisting Concerns — Sep 16, 2024 Risk: high
  FibroGen, Inc. filed an 8-K on September 12, 2024, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company is ba
• FibroGen Announces Executive Compensation Changes — Sep 13, 2024 Risk: low
  FibroGen, Inc. announced on September 12, 2024, changes in its executive compensation arrangements. Specifically, the company entered into a new employment agre
• FibroGen Appoints New Chief Medical Officer — Sep 6, 2024 Risk: medium
  FibroGen, Inc. announced on August 30, 2024, the appointment of Dr. K. Peter R. Nielsen as Chief Medical Officer and Executive Vice President. Dr. Nielsen previ
• FibroGen Sells Rimantadine Rights to Eton for $10M — Aug 7, 2024 Risk: low
  FibroGen, Inc. reported on August 2, 2024, that it has entered into a definitive agreement to sell its U.S. rights to Rimantadine Hydrochloride to Eton Pharmace
• 8-K Filing — Jun 26, 2024
• FibroGen Files 8-K: Shareholder Vote & Financials Update — Jun 7, 2024 Risk: low
  FibroGen, Inc. filed an 8-K on June 7, 2024, reporting a submission of matters to a vote of security holders and financial statements/exhibits as of June 5, 202

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX